The HIVE Community

The Health Innovation Virtual Engagement (HIVE) community supports Canadian dermatologists, allergists, immunologists and others with an interest in urticaria to support collaboration and enhance understanding of this condition.

Latest from HIVE

The Buzz, Issue #14 is now out! In this month’s issue, we highlight a possible new predictive biomarker for severe anaphylaxis in children, the use of direct oral challenge to de-label penicillin allergy during pregnancy, and three publications in atopic dermatitis: new data with the JAK1-selective inhibitor abrocitinib, a structured appraisal of the clinical practice guidelines, and a metaanalysis of the literature on the use of dilute bleach baths.

The Buzz Issue #14, June 2022 edition, will be sent to all HIVE members by email on Mon, May 30th, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz

The HIVE Refresh!

Dear HIVE members, We looked for your feedback, reflected upon it and refreshed our purpose and process to go beyond Chronic Spontaneous Urticaria (CSU) to include keywords of common interest to allergists, immunologists and dermatologists. You will see this reflected in your weekly HIVE email digest, in the “New Articles From Your Sources” section as … Continue reading The HIVE Refresh!

The Buzz, Issue #13 is now out! This month’s publications look at peanut cross-contamination rates, the safety of second SARS-CoV-2 vaccine doses following an immediate allergic reaction to dose 1, the risk of thyroid autoimmunity in the setting of chronic urticaria, a review of cannabis-related allergy, and another scoping review about culprit drug identification.

The Buzz Issue #13, May 2022 edition, will be sent to all HIVE members by email on Mon, May 2nd, and can be accessed online here. To view all issues of The Buzz, go to thehivecommunity.org/the-buzz